Le Lézard
Classified in: Ebola virus, Health, Science and technology
Subjects: CCA, BFA

Aethlon Medical to Release Financial Results for the Second Quarter Fiscal Year 2018 and Host Conference Call on November 2, 2017



SAN DIEGO, Oct. 30, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense today announced it will issue financial results for the second quarter fiscal year 2018 ended September 30, 2017 at 4:15pm eastern time on Thursday, November 2, 2017.

Management will host a conference call on Thursday, November 2, 2017 at 4:30pm eastern time to review financial results and corporate highlights. Following management's formal remarks, there will be a question and answer session.

To listen to the call by phone, interested parties within the U.S. should call 1-844-836-8741 and International callers should call 1-412-317-5442. All callers should ask for the Aethlon Medical Inc., conference call. The conference call will also be available through a live webcast at www.aethlonmedical.com. Details for the webcast may be found on the Company's IR events page at http://ir.aethlonmedical.com.

A replay of the call will be available approximately one hour after the end of the call through November 9, 2017. The replay can be accessed via Aethlon Medical's website or by dialing 1-877-344-7529 (domestic) or 1-412-317-0088 (international) or Canada Toll Free at 1-855-669-9658. The replay conference ID number is 10114031.

About Aethlon Medical, Inc.

Aethlon Medical is focused on addressing unmet needs in global health and biodefense. The Aethlon Hemopurifier® is a first-in-class therapeutic device designed to address life-threatening viral infections.  The United States Food and Drug Administration (FDA) has designated the Hemopurifier® to an Expedited Access Pathway (EAP) related to the treatment of life-threatening viruses that are not addressed with approved therapies.

In collaboration with leading government and non-government research institutes, Aethlon has validated the ability of the Hemopurifier® to capture a broad-spectrum of pandemic influenza viruses, mosquito-borne viruses and deadly hemorrhagic viruses.  Based on its use to treat Ebola virus, the Hemopurifier® was named a "Top 25 Invention" and one of the "Eleven Most Remarkable Advances in Healthcare," by TIME Magazine.

Aethlon is also investigating the potential therapeutic use of the Hemopurifier® to reduce the presence of tumor-derived exosomes, which contribute to immune-suppression and the spread of metastasis in cancer patients.  Additionally, Aethlon is the majority owner of Exosome Sciences, Inc. (ESI), which is focused on the discovery of exosomal biomarkers to diagnose and monitor cancer and neurological disorders, including Alzheimer's disease (AD) and Chronic Traumatic Encephalopathy (CTE).  Additional information can be found online at www.AethlonMedical.com and www.ExosomeSciences.com.  You can also connect with us on Twitter, LinkedIn, Facebook and Google+.

Company Contact:
Jim Frakes
Chief Financial Officer
Aethlon Medical, Inc.
858-459-7800 extension 3300
Jfrakes@aethlonmedical.com

Investor Relations:
John Marco
CORE IR
516 222 2560
johnm@coreir.com

 

SOURCE Aethlon Medical, Inc.


These press releases may also interest you

at 14:01
After just a year in business, Dr. Keith Ablow, the renowned psychiatrist, New York Times bestselling self-help author and television personality has doubled the size of Blue Water Wellness his Newburyport, MA mind-body medspa. Dr. Ablow was the...

at 14:00
It's no secret that pets make our lives happier and healthier. And for many families, the benefits pets provide will soon come at a time and place they may never have expected: during their child's hospital stay. Today, Mars Petcare and Monroe Carell...

at 14:00
The "US Product Portfolio for Interventional Cardiology 2018 - MedFolio" report has been added to ResearchAndMarkets.com's offering. There are many different types of complementary devices used during interventional cardiology procedures. These...

at 14:00
FLUSHING, N.Y., July 18, 2018 /PRNewswire-PRWeb/ -- Calcium & Bone Health Institute (CBHI), partnering with Pronuvia, Inc., has initiated to introduce the revolutionary Sigma Anti-Bonding Calcium (SAC) to medical industry. Recently, the inventor of...

at 14:00
Alcami Corporation, a leading provider of fully-integrated custom end-to-end solutions for the pharmaceutical and biotechnology industries, today announced a renewed partnership with the Wisconsin Department of Natural Resources (DNR) to revitalize...

at 13:58
Care Bridge International, a data analytics firm, today announced a new white paper that uses a massive claims database to estimate the true exposure of future medical treatment and costs in Medicare Set Asides for Workers Compensation claims.  The...




News published on 30 october 2017 at 07:30 and distributed by: